Association Between Nonalcoholic Hepatic Steatosis and Hepatic Cytochrome P-450 3A Activity

Dhanashri Kolwankar, Raj Vuppalanchi, Brian Ethell, David R. Jones, Steven A. Wrighton, Stephen D. Hall, Naga Chalasani

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background & Aims: Comorbidities associated with nonalcoholic fatty liver often require therapy with medications (eg, statins) metabolized by cytochrome P-450 3A (CYP3A). There is significant interindividual variability in CYP3A expression. However, human studies that systematically examined the relationship between hepatic steatosis and hepatic CYP3A activity are lacking. Methods: The relationship of hepatic CYP3A activity with several variables including hepatic steatosis, CYP3A4 protein content, CYP3A4 mRNA expression, CYP3A5 genotype, and its mRNA expression was investigated in human liver samples (n = 49). CYP3A activity was quantified from liver microsomes by using testosterone as a probe, and hepatic steatosis was defined to be present if >5% of hepatocytes had large globules of intracellular fat displacing the nucleus. Results: The mean ± standard error hepatic CYP3A activity of the study group was 3156 ± 2794 pmol · min-1 · mg-1 of protein, and it was not associated with age, gender, medicinal use, CYP3A5 or pregnane xenobiotic receptor mRNA expression, or CYP3A5 genotype. Twenty-four liver samples with steatosis had significantly lower hepatic CYP3A activity than 25 liver samples without steatosis (1978 ± 299 vs 4287 ± 659 pmol · min-1 · mg-1 of protein; P = .003). This difference persisted even after controlling for relevant covariates in the multivariate analysis (P = .04). However, CYP3A4 protein content was not different between the 2 groups (6 ± 1.3 vs 8.5 ± 2.2 pmol/mg protein; P = .3). There was a significant negative relationship between severity of steatosis and hepatic CYP3A activity (P = .01). Conclusions: Hepatic steatosis is associated with decreased hepatic CYP3A activity in humans via post-translational mechanism. Further studies are needed to confirm our findings.

Original languageEnglish
Pages (from-to)388-393
Number of pages6
JournalClinical Gastroenterology and Hepatology
Volume5
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Cytochrome P-450 Enzyme System
Cytochrome P-450 CYP3A
Liver
Proteins
Messenger RNA
Genotype
Pregnanes
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Liver Microsomes
Xenobiotics
Human Activities
Testosterone
Comorbidity
Hepatocytes
Multivariate Analysis
Fats

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Association Between Nonalcoholic Hepatic Steatosis and Hepatic Cytochrome P-450 3A Activity. / Kolwankar, Dhanashri; Vuppalanchi, Raj; Ethell, Brian; Jones, David R.; Wrighton, Steven A.; Hall, Stephen D.; Chalasani, Naga.

In: Clinical Gastroenterology and Hepatology, Vol. 5, No. 3, 03.2007, p. 388-393.

Research output: Contribution to journalArticle

Kolwankar, Dhanashri ; Vuppalanchi, Raj ; Ethell, Brian ; Jones, David R. ; Wrighton, Steven A. ; Hall, Stephen D. ; Chalasani, Naga. / Association Between Nonalcoholic Hepatic Steatosis and Hepatic Cytochrome P-450 3A Activity. In: Clinical Gastroenterology and Hepatology. 2007 ; Vol. 5, No. 3. pp. 388-393.
@article{9d632bba07b343cd87dea2628a120529,
title = "Association Between Nonalcoholic Hepatic Steatosis and Hepatic Cytochrome P-450 3A Activity",
abstract = "Background & Aims: Comorbidities associated with nonalcoholic fatty liver often require therapy with medications (eg, statins) metabolized by cytochrome P-450 3A (CYP3A). There is significant interindividual variability in CYP3A expression. However, human studies that systematically examined the relationship between hepatic steatosis and hepatic CYP3A activity are lacking. Methods: The relationship of hepatic CYP3A activity with several variables including hepatic steatosis, CYP3A4 protein content, CYP3A4 mRNA expression, CYP3A5 genotype, and its mRNA expression was investigated in human liver samples (n = 49). CYP3A activity was quantified from liver microsomes by using testosterone as a probe, and hepatic steatosis was defined to be present if >5{\%} of hepatocytes had large globules of intracellular fat displacing the nucleus. Results: The mean ± standard error hepatic CYP3A activity of the study group was 3156 ± 2794 pmol · min-1 · mg-1 of protein, and it was not associated with age, gender, medicinal use, CYP3A5 or pregnane xenobiotic receptor mRNA expression, or CYP3A5 genotype. Twenty-four liver samples with steatosis had significantly lower hepatic CYP3A activity than 25 liver samples without steatosis (1978 ± 299 vs 4287 ± 659 pmol · min-1 · mg-1 of protein; P = .003). This difference persisted even after controlling for relevant covariates in the multivariate analysis (P = .04). However, CYP3A4 protein content was not different between the 2 groups (6 ± 1.3 vs 8.5 ± 2.2 pmol/mg protein; P = .3). There was a significant negative relationship between severity of steatosis and hepatic CYP3A activity (P = .01). Conclusions: Hepatic steatosis is associated with decreased hepatic CYP3A activity in humans via post-translational mechanism. Further studies are needed to confirm our findings.",
author = "Dhanashri Kolwankar and Raj Vuppalanchi and Brian Ethell and Jones, {David R.} and Wrighton, {Steven A.} and Hall, {Stephen D.} and Naga Chalasani",
year = "2007",
month = "3",
doi = "10.1016/j.cgh.2006.12.021",
language = "English",
volume = "5",
pages = "388--393",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Association Between Nonalcoholic Hepatic Steatosis and Hepatic Cytochrome P-450 3A Activity

AU - Kolwankar, Dhanashri

AU - Vuppalanchi, Raj

AU - Ethell, Brian

AU - Jones, David R.

AU - Wrighton, Steven A.

AU - Hall, Stephen D.

AU - Chalasani, Naga

PY - 2007/3

Y1 - 2007/3

N2 - Background & Aims: Comorbidities associated with nonalcoholic fatty liver often require therapy with medications (eg, statins) metabolized by cytochrome P-450 3A (CYP3A). There is significant interindividual variability in CYP3A expression. However, human studies that systematically examined the relationship between hepatic steatosis and hepatic CYP3A activity are lacking. Methods: The relationship of hepatic CYP3A activity with several variables including hepatic steatosis, CYP3A4 protein content, CYP3A4 mRNA expression, CYP3A5 genotype, and its mRNA expression was investigated in human liver samples (n = 49). CYP3A activity was quantified from liver microsomes by using testosterone as a probe, and hepatic steatosis was defined to be present if >5% of hepatocytes had large globules of intracellular fat displacing the nucleus. Results: The mean ± standard error hepatic CYP3A activity of the study group was 3156 ± 2794 pmol · min-1 · mg-1 of protein, and it was not associated with age, gender, medicinal use, CYP3A5 or pregnane xenobiotic receptor mRNA expression, or CYP3A5 genotype. Twenty-four liver samples with steatosis had significantly lower hepatic CYP3A activity than 25 liver samples without steatosis (1978 ± 299 vs 4287 ± 659 pmol · min-1 · mg-1 of protein; P = .003). This difference persisted even after controlling for relevant covariates in the multivariate analysis (P = .04). However, CYP3A4 protein content was not different between the 2 groups (6 ± 1.3 vs 8.5 ± 2.2 pmol/mg protein; P = .3). There was a significant negative relationship between severity of steatosis and hepatic CYP3A activity (P = .01). Conclusions: Hepatic steatosis is associated with decreased hepatic CYP3A activity in humans via post-translational mechanism. Further studies are needed to confirm our findings.

AB - Background & Aims: Comorbidities associated with nonalcoholic fatty liver often require therapy with medications (eg, statins) metabolized by cytochrome P-450 3A (CYP3A). There is significant interindividual variability in CYP3A expression. However, human studies that systematically examined the relationship between hepatic steatosis and hepatic CYP3A activity are lacking. Methods: The relationship of hepatic CYP3A activity with several variables including hepatic steatosis, CYP3A4 protein content, CYP3A4 mRNA expression, CYP3A5 genotype, and its mRNA expression was investigated in human liver samples (n = 49). CYP3A activity was quantified from liver microsomes by using testosterone as a probe, and hepatic steatosis was defined to be present if >5% of hepatocytes had large globules of intracellular fat displacing the nucleus. Results: The mean ± standard error hepatic CYP3A activity of the study group was 3156 ± 2794 pmol · min-1 · mg-1 of protein, and it was not associated with age, gender, medicinal use, CYP3A5 or pregnane xenobiotic receptor mRNA expression, or CYP3A5 genotype. Twenty-four liver samples with steatosis had significantly lower hepatic CYP3A activity than 25 liver samples without steatosis (1978 ± 299 vs 4287 ± 659 pmol · min-1 · mg-1 of protein; P = .003). This difference persisted even after controlling for relevant covariates in the multivariate analysis (P = .04). However, CYP3A4 protein content was not different between the 2 groups (6 ± 1.3 vs 8.5 ± 2.2 pmol/mg protein; P = .3). There was a significant negative relationship between severity of steatosis and hepatic CYP3A activity (P = .01). Conclusions: Hepatic steatosis is associated with decreased hepatic CYP3A activity in humans via post-translational mechanism. Further studies are needed to confirm our findings.

UR - http://www.scopus.com/inward/record.url?scp=33947099408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947099408&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2006.12.021

DO - 10.1016/j.cgh.2006.12.021

M3 - Article

C2 - 17368239

AN - SCOPUS:33947099408

VL - 5

SP - 388

EP - 393

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 3

ER -